Michael Schäfers
Westfälische Wilhelms-Universität Münster
H-index: 71
Europe-Germany
Description
Michael Schäfers, With an exceptional h-index of 71 and a recent h-index of 41 (since 2020), a distinguished researcher at Westfälische Wilhelms-Universität Münster, specializes in the field of Nuclear Medicine / Molecular Imaging.
His recent articles reflect a diverse array of research interests and contributions to the field:
TFB-PET/CT im Vergleich zum posttherapeutischen Hochdosis Iod-131-SPECT/CT und FDG-PET/CT im fortgeschrittenen differenzierten Schilddrüsenkarzinom
Radiomics-Based Prediction Model for Outcome of Radioembolization in Metastatic Colorectal Cancer
Totalsynthese und Radiomarkierung von Salmochelin B ([68Ga] Ga-RMA693) für die Bakterien-spezifische Bildgebung
Diagnostic Performance of [18F] TFB PET/CT Compared with Therapeutic Activity [131I] Iodine SPECT/CT and [18F] FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma
Installing alternating ionic charges on radiolabeled tracers to improve PET-imaging
A novel radiolabelled salmochelin derivative for bacteria-specific PET imaging: synthesis, radiolabelling and evaluation
[18F] FDG-und [18F] FAPI-74-PET bei Patienten mit Radioiod-refraktärem differenzierten Scilddrüsenkarzinom
Safety and Efficacy of Extended Therapy with [177Lu] Lu-PSMA: A German Multicenter Study
Professor Information
University | Westfälische Wilhelms-Universität Münster |
---|---|
Position | Professor of Nuclear Medicine and Molecuar Imaging |
Citations(all) | 17080 |
Citations(since 2020) | 7420 |
Cited By | 12455 |
hIndex(all) | 71 |
hIndex(since 2020) | 41 |
i10Index(all) | 255 |
i10Index(since 2020) | 155 |
University Profile Page | Westfälische Wilhelms-Universität Münster |
Research & Interests List
Nuclear Medicine / Molecular Imaging
Top articles of Michael Schäfers
TFB-PET/CT im Vergleich zum posttherapeutischen Hochdosis Iod-131-SPECT/CT und FDG-PET/CT im fortgeschrittenen differenzierten Schilddrüsenkarzinom
Ziel/Aim: F-18-Tetrafluorborat (TFB) ist ein vielversprechendes PET-Radiopharmakon mit exzellenten Eigenschaften für die Bildgebung des Natrium-Iodid-Symporters (NIS) bei Patienten mit differenziertem Schilddrüsenkarzinom (DTC). Ziel dieser Studie war der Vergleich des TFB-PET mit der Hochdosis posttherapeutischen Iod-131-Ganzkörperszintigraphie/SPECT/CT (TxWBS-SPECT/CT) bei Patienten mit einem Rezidiv des DTC und zum FDG-PET in entdifferenzierten Läsionen.Methodik/Methods: Insgesamt wurden 26 Patienten die eine hochdosierte Radioiodtherapie (RAI) mit Iod-131 (5, 0–10, 2 GBq) zwischen Mai 2020 und November 2022 erhielten in diese retrospektive Studie eingeschlossen. Alle Patienten wurden vor der Therapie mittels TFB-PET/CT 40 Minuten nach Injektion im median von 321 MBq F-18-TFB untersucht. Zum Vergleich der Tracer-Kinetik wurden zusätzlich 23/26 Patienten nach 90 …
Authors
D Ventura,M Dittmann,F Büther,M Schäfers,K Rahbar,D Hescheler,M Claesener,P Schindler,B Riemann,R Seifert,W Roll
Journal
Nuklearmedizin-NuclearMedicine
Published Date
2024/4
Radiomics-Based Prediction Model for Outcome of Radioembolization in Metastatic Colorectal Cancer
PurposeTo evaluate the benefit of a contrast-enhanced computed tomography (CT) radiomics-based model for predicting response and survival in patients with colorectal liver metastases treated with transarterial Yttrium-90 radioembolization (TARE).Materials and MethodsFifty-one patients who underwent TARE were included in this single-center retrospective study. Response to treatment was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at 3-month follow-up. Patients were stratified as responders (complete/partial response and stable disease, n= 24) or non-responders (progressive disease, n= 27). Radiomic features (RF) were extracted from pre-TARE CT after segmentation of the liver tumor volume. A model was built based on a radiomic signature consisting of reliable RFs that allowed classification of response using multivariate logistic regression. Patients were assigned to …
Authors
Wolfgang Roll,Max Masthoff,Michael Köhler,Kambiz Rahbar,Lars Stegger,David Ventura,Haluk Morgül,Jonel Trebicka,Michael Schäfers,Walter Heindel,Moritz Wildgruber,Philipp Schindler
Journal
CardioVascular and Interventional Radiology
Published Date
2024/2/28
Totalsynthese und Radiomarkierung von Salmochelin B ([68Ga] Ga-RMA693) für die Bakterien-spezifische Bildgebung
Ziel/Aim: Bakterielle Infektionen haben oft ein unspezifisches klinisches Erscheinungsbild. Die Unterscheidung zwischen infektiösen und nicht-infektiösen Herden und deren Lokalisation sind jedoch wichtig für eine optimale Therapie. Um bakterielle Infektionen spezifisch bildgebend darzustellen, bearbeiten wir neben der spezifischen Aufnahme von besonderen Kohlenhydraten auch das bakteriell spezifische Eisentransportsystem (via Siderophore), wobei Eisen durch Ga-68 ersetzt wird.Methodik/Methods: In einer konvergenten Totalsynthese wurde aus kommerziell erhältlichen Bausteinen Salmochelin B (C-glykosyliertes Enterobaktin) als Präkursor erhalten. Nach radioaktiver Markierung mit Ga-68 wurde [68 Ga] Ga-RMA693 sowohl auf Stabilität in humanem und murinem Serum als auch in vitro auf die Spezifität der Aufnahme in E. coli-Stämmen getestet. Anschließend wurde die Biodistribution beurteilt und in …
Authors
A Faust,R Margeta,S Schelhaas,S Hermann,M Schäfers,S Niemann
Journal
Nuklearmedizin-NuclearMedicine
Published Date
2024/4
Diagnostic Performance of [18F] TFB PET/CT Compared with Therapeutic Activity [131I] Iodine SPECT/CT and [18F] FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma
[18F]tetrafluoroborate ([18F]TFB) is an emerging PET tracer with excellent properties for human sodium iodide symporter (NIS)–based imaging in patients with differentiated thyroid cancer (DTC). The aim of this study was to compare [18F]TFB PET with high-activity posttherapeutic [131I]iodine whole-body scintigraphy and SPECT/CT in recurrent DTC and with [18F]FDG PET/CT in suspected dedifferentiation. Methods Twenty-six patients treated with high-activity radioactive [131I]iodine therapy (range, 5.00–10.23 GBq) between May 2020 and November 2022 were retrospectively included. Thyroid-stimulating hormone was stimulated by 2 injections of recombinant thyroid-stimulating hormone (0.9 mg) 48 and 24 h before therapy. Before treatment, all patients underwent [18F]TFB PET/CT 40 min after injection of a median of 321 MBq of [18F]TFB. To study tracer kinetics in DTC lesions, 23 patients received an …
Authors
David Ventura,Matthias Dittmann,Florian Büther,Michael Schäfers,Kambiz Rahbar,Daniel Hescheler,Michael Claesener,Philipp Schindler,Burkhard Riemann,Robert Seifert,Wolfgang Roll
Journal
Journal of Nuclear Medicine
Published Date
2024/2/1
Installing alternating ionic charges on radiolabeled tracers to improve PET-imaging
Ziel/Aim: Low signal to background and fast liver clearance are problematic properties of radiopharmaceuticals. To address this problem barbiturates as MMP-targeting ligands were chosen as test compounds due to their on the one hand high binding affinity but on the other high liver uptake and unspecific binding. To improve their properties, alternating ionic charges should have strong influence on their pharmacokinetic behavior.Methodik/Methods: A balanced net charged amino acid sequence (pH 7.4) was introduced on the barbiturate based radiotracer as a spacer via convergent synthesis. Apart from that, NOTA was chosen due to its suitability to chelate with Ga-68 or (Al) F-18. Characterization and affinity assay of cold references have been performed and both variants were successfully radiolabelled. Serum stability, logD-value and biodistribution were examined.
Authors
S Palakhachane,K Schwegmann,S Höppner,CA Strassert,M Schäfers,A Faust
Journal
Nuklearmedizin-NuclearMedicine
Published Date
2024/4
A novel radiolabelled salmochelin derivative for bacteria-specific PET imaging: synthesis, radiolabelling and evaluation
For specific imaging of bacterial infections we aimed at targeting the exclusive bacterial iron transport system via siderophore-based radiotracers. De novo synthesis and radiolabeling yielded the salmochelin-based PET radiotracer [68Ga]Ga-RMA693, which showed a favourable biodistribution and a bacteria-specific uptake in an animal model of Escherichia coli infection.
Authors
Renato Margeta,Sonja Schelhaas,Sven Hermann,Michael Schafers,Silke Niemann,Andreas Faust
Journal
Chemical Communications
Published Date
2024
[18F] FDG-und [18F] FAPI-74-PET bei Patienten mit Radioiod-refraktärem differenzierten Scilddrüsenkarzinom
Ziel/Aim: In einigen Studien in gemischten Kollektiven von Schilddrüsenkarzinom-Patienten zeigte die FAPI-PET/CT verbesserte Bildgebungseigenschaft im Vergleich zur [18 F] FDG-PET/CT. Mit dieser Zwischenanalyse einer prospektiven Studie soll untersucht werden, ob [18 F] FAPI-74 dem [18 F] FDG-PET/CT in der speziellen Untergruppe des Radioiod (RAI)-refraktären differenzierten Schilddrüsenkarzinoms (DTC) überlegen ist.Methodik/Methods: 10 Patienten mit rezidivierendem DTC, nachgewiesen durch erhöhtes Thyreoglobulin, mit negativem RAI-Scan nach Thyreoidektomie und RAI-Therapie wurden prospektiv eingeschlossen. Bei allen Patienten wurde ein [18 F] FAPI-74-und ein [18 F] FDG-PET/CT durchgeführt. Es erfolgte eine Patienten-und Läsions-basierte Analyse.
Authors
W Roll,P Hadjitheodorou,E Alevroudis,K Kyrou,MR Pourkhessalian,G Adamou,A Fesas,C Kalogirou,M Schäfers,A Vrachimis
Journal
Nuklearmedizin-NuclearMedicine
Published Date
2024/4
Safety and Efficacy of Extended Therapy with [177Lu] Lu-PSMA: A German Multicenter Study
Prospective results have demonstrated favorable safety and efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy for up to 6 cycles in men with metastatic castration-resistant prostate cancer. However, no systematic data are available outlining the feasibility of extended therapy beyond 6 cycles. We aim to evaluate the safety and efficacy of extended [177Lu]Lu-PSMA radiopharmaceutical therapy in patients who have received more than 6 cycles. Methods In total, 111 patients were included in this multicenter retrospective analysis. Based on individual decisions, patients underwent uninterrupted continuation of therapy (continuous treatment) or reexposure after a therapy break (rechallenge treatment) between 2014 and 2023. Overall survival, 50% prostate-specific antigen (PSA) decline (measured 8–12 wk after treatment initiation or rechallenge), PSMA PET response, and grades per Common Terminology …
Authors
Robert Seifert,Tugce Telli,Constantin Lapa,Mélanie Desaulniers,Turkay Hekimsoy,Wolfgang A Weber,Christian Pfob,Boris Hadaschik,Martin Bögemann,Michael Schäfers,Ken Herrmann,Kambiz Rahbar,Matthias Eiber,Wolfgang P Fendler
Journal
Journal of Nuclear Medicine
Published Date
2024/5/2
Professor FAQs
What is Michael Schäfers's h-index at Westfälische Wilhelms-Universität Münster?
The h-index of Michael Schäfers has been 41 since 2020 and 71 in total.
What are Michael Schäfers's top articles?
The articles with the titles of
TFB-PET/CT im Vergleich zum posttherapeutischen Hochdosis Iod-131-SPECT/CT und FDG-PET/CT im fortgeschrittenen differenzierten Schilddrüsenkarzinom
Radiomics-Based Prediction Model for Outcome of Radioembolization in Metastatic Colorectal Cancer
Totalsynthese und Radiomarkierung von Salmochelin B ([68Ga] Ga-RMA693) für die Bakterien-spezifische Bildgebung
Diagnostic Performance of [18F] TFB PET/CT Compared with Therapeutic Activity [131I] Iodine SPECT/CT and [18F] FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma
Installing alternating ionic charges on radiolabeled tracers to improve PET-imaging
A novel radiolabelled salmochelin derivative for bacteria-specific PET imaging: synthesis, radiolabelling and evaluation
[18F] FDG-und [18F] FAPI-74-PET bei Patienten mit Radioiod-refraktärem differenzierten Scilddrüsenkarzinom
Safety and Efficacy of Extended Therapy with [177Lu] Lu-PSMA: A German Multicenter Study
...
are the top articles of Michael Schäfers at Westfälische Wilhelms-Universität Münster.
What are Michael Schäfers's research interests?
The research interests of Michael Schäfers are: Nuclear Medicine / Molecular Imaging
What is Michael Schäfers's total number of citations?
Michael Schäfers has 17,080 citations in total.
What are the co-authors of Michael Schäfers?
The co-authors of Michael Schäfers are Paulus Kirchhof, Prof. Dr. Markus van der Giet, Larissa Fabritz, CL Fabritz, FL Fabritz, Ulrich Flögel, Gregor Theilmeier, Moritz Wildgruber MD, PhD.